{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:22:41Z","timestamp":1789150961178,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Opioid use disorder (OUD) is a major source of morbidity and mortality in the U.S. and there is a pressing need to identify additional treatments for the disorder. Classic psychedelics (psilocybin, peyote, mescaline, LSD) have been linked to the alleviation of various substance use disorders and may hold promise as potential treatments for OUD. The aim of this study was to assess whether the aforementioned classic psychedelic substances conferred lowered odds of OUD. Furthermore, this study aimed to replicate and extend findings from Pisano et al. (2017) who found classic psychedelic use to be linked to lowered odds of OUD in a nationally representative sample. We used recent data from the National Survey on Drug Use and Health (2015\u20132019) (<jats:italic>N<\/jats:italic>\u2009=\u2009214,505) and multivariable logistic regression to test whether lifetime use (yes\/no) of classic psychedelics was associated with lowered odds of OUD. Lifetime psilocybin use was associated with lowered odds of OUD (aOR: 0.70; 95% CI [0.60, 0.83]). No other substances, including other classic psychedelics, were associated with lowered odds of OUD. Additionally, sensitivity analyses revealed psilocybin use to be associated with lowered odds of seven of the 11 DSM-IV criteria for OUD (aOR range: 0.66\u20130.83). Future clinical trials and longitudinal studies are needed to determine whether these associations are causal.<\/jats:p>","DOI":"10.1038\/s41598-022-08085-4","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T16:02:49Z","timestamp":1649347369000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample"],"prefix":"10.1038","volume":"12","author":[{"given":"Grant","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn A.","family":"Ricard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Lipson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew K.","family":"Nock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,7]]},"reference":[{"key":"8085_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.0217","volume":"1","author":"T Gomes","year":"2018","unstructured":"Gomes, T., Tadrous, M., Mamdani, M. M., Paterson, J. M. & Juurlink, D. N. The burden of opioid-related mortality in the United States. JAMA Netw. Open 1, e180217 (2018).","journal-title":"JAMA Netw. Open"},{"key":"8085_CR2","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/HRP.0000000000000052","volume":"23","author":"Y-I Hser","year":"2015","unstructured":"Hser, Y.-I., Evans, E., Grella, C., Ling, W. & Anglin, D. Long-term course of opioid addiction. Harv. Rev. Psychiatry 23, 76\u201389 (2015).","journal-title":"Harv. Rev. Psychiatry"},{"key":"8085_CR3","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7006a4","author":"CL Mattson","year":"2021","unstructured":"Mattson, C. L. Trends and geographic patterns in drug and synthetic opioid overdose deaths\u2014United States, 2013\u20132019. MMWR Morb. Mortal. Wkly. Rep. https:\/\/doi.org\/10.15585\/mmwr.mm7006a4 (2021).","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"8085_CR4","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.2105\/AJPH.2021.306256","volume":"111","author":"J Friedman","year":"2021","unstructured":"Friedman, J. & Akre, S. COVID-19 and the drug overdose crisis: Uncovering the deadliest months in the United States, January\u2013July 2020. Am. J. Public Health 111, 1284\u20131291 (2021).","journal-title":"Am. J. Public Health"},{"key":"8085_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2021.106845","volume":"153","author":"J Friedman","year":"2021","unstructured":"Friedman, J. et al. Growing racial\/ethnic disparities in overdose mortality before and during the COVID-19 pandemic in California. Prev. Med. 153, 106845 (2021).","journal-title":"Prev. Med."},{"key":"8085_CR6","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1037\/0033-2909.112.1.64","volume":"112","author":"JD Hawkins","year":"1992","unstructured":"Hawkins, J. D., Catalano, R. F. & Miller, J. Y. Risk and protective factors for alcohol and other drug problems in adolescence and early adulthood: Implications for substance abuse prevention. Psychol. Bull. 112, 64\u2013105 (1992).","journal-title":"Psychol. Bull."},{"key":"8085_CR7","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1056\/NEJMoa1505409","volume":"374","author":"JD Lee","year":"2016","unstructured":"Lee, J. D. et al. Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. N. Engl. J. Med. 374, 1232\u20131242 (2016).","journal-title":"N. Engl. J. Med."},{"key":"8085_CR8","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1056\/NEJMsr1706626","volume":"377","author":"ND Volkow","year":"2017","unstructured":"Volkow, N. D. & Collins, F. S. The role of science in addressing the opioid crisis. N. Engl. J. Med. 377, 391\u2013394 (2017).","journal-title":"N. Engl. J. Med."},{"key":"8085_CR9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.pharmthera.2018.11.010","volume":"197","author":"MW Johnson","year":"2019","unstructured":"Johnson, M. W., Hendricks, P. S., Barrett, F. S. & Griffiths, R. R. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacol. Ther. 197, 83\u2013102 (2019).","journal-title":"Pharmacol. Ther."},{"key":"8085_CR10","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.pnpbp.2015.03.002","volume":"64","author":"MP Bogenschutz","year":"2016","unstructured":"Bogenschutz, M. P. & Johnson, M. W. Classic hallucinogens in the treatment of addictions. Prog. Neuropsychopharmacol. Biol. Psychiatry 64, 250\u2013258 (2016).","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"8085_CR11","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/0269881114548296","volume":"28","author":"MW Johnson","year":"2014","unstructured":"Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. & Griffiths, R. R. Pilot study of the 5-HT2A R agonist psilocybin in the treatment of tobacco addiction. J. Psychopharmacol. 28, 983\u2013992 (2014).","journal-title":"J. Psychopharmacol."},{"key":"8085_CR12","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1177\/0269881112439253","volume":"26","author":"TS Krebs","year":"2012","unstructured":"Krebs, T. S. & Johansen, P. -\u00d8. Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials. J. Psychopharmacol. 26, 994\u20131002 (2012).","journal-title":"J. Psychopharmacol."},{"key":"8085_CR13","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3389\/fpsyt.2019.00955","volume":"10","author":"A Garcia-Romeu","year":"2020","unstructured":"Garcia-Romeu, A. et al. Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: An online survey. Front. Psychiatry 10, 955 (2020).","journal-title":"Front. Psychiatry"},{"key":"8085_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103518","volume":"100","author":"E Argento","year":"2022","unstructured":"Argento, E. et al. Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting. Int. J. Drug Policy 100, 103518 (2022).","journal-title":"Int. J. Drug Policy"},{"key":"8085_CR15","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1177\/0269881117691453","volume":"31","author":"VD Pisano","year":"2017","unstructured":"Pisano, V. D. et al. The association of psychedelic use and opioid use disorders among illicit users in the United States. J. Psychopharmacol. 31, 606\u2013613 (2017).","journal-title":"J. Psychopharmacol."},{"key":"8085_CR16","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1038\/s41598-022-06580-2","volume":"12","author":"GM Jones","year":"2022","unstructured":"Jones, G. M. & Nock, M. K. Exploring protective associations between the use of classic psychedelics and cocaine use disorder: A population-based survey study. Sci. Rep. 12, 2574 (2022).","journal-title":"Sci. Rep."},{"key":"8085_CR17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/02698811211066714","volume":"36","author":"GM Jones","year":"2022","unstructured":"Jones, G. M. & Nock, M. K. Lifetime use of MDMA\/ecstasy and psilocybin is associated with reduced odds of major depressive episodes. J. Psychopharmacol. 36, 57\u201365 (2022).","journal-title":"J. Psychopharmacol."},{"key":"8085_CR18","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1177\/02698811211058933","volume":"36","author":"GM Jones","year":"2022","unstructured":"Jones, G. M. & Nock, M. K. Psilocybin use is associated with lowered odds of crime arrests in US adults: A replication and extension. J. Psychopharmacol. 36, 66\u201373 (2022).","journal-title":"J. Psychopharmacol."},{"key":"8085_CR19","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1177\/02698811211058923","volume":"36","author":"GM Jones","year":"2022","unstructured":"Jones, G. M. & Nock, M. K. MDMA\/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults. J. Psychopharmacol. 36, 46\u201356 (2022).","journal-title":"J. Psychopharmacol."},{"key":"8085_CR20","unstructured":"Lumley, T. Survey: Analysis of Complex Survey Samples (2020)."},{"key":"8085_CR21","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV, Washington DC (1994)."},{"key":"8085_CR22","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1007\/s13311-017-0542-y","volume":"14","author":"MW Johnson","year":"2017","unstructured":"Johnson, M. W. & Griffiths, R. R. Potential therapeutic effects of psilocybin. Neurotherapeutics 14, 734\u2013740 (2017).","journal-title":"Neurotherapeutics"},{"key":"8085_CR23","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols, D. E. Psychedelics. Pharmacol. Rev. 68, 264\u2013355 (2016).","journal-title":"Pharmacol. Rev."},{"key":"8085_CR24","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1002\/dta.1376","volume":"4","author":"MP Bogenschutz","year":"2012","unstructured":"Bogenschutz, M. P. & Pommy, J. M. Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: From indirect evidence to testable hypotheses. Drug Test. Anal. 4, 543\u2013555 (2012).","journal-title":"Drug Test. Anal."},{"key":"8085_CR25","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.neuropharm.2013.06.030","volume":"76","author":"KA Cunningham","year":"2014","unstructured":"Cunningham, K. A. & Anastasio, N. C. Serotonin at the nexus of impulsivity and cue reactivity in cocaine addiction. Neuropharmacology 76, 460\u2013478 (2014).","journal-title":"Neuropharmacology"},{"key":"8085_CR26","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1124\/pr.114.009514","volume":"67","author":"LL Howell","year":"2015","unstructured":"Howell, L. L. & Cunningham, K. A. Serotonin 5-HT2 receptor interactions with dopamine function: Implications for therapeutics in cocaine use disorder. Pharmacol. Rev. 67, 176\u2013197 (2015).","journal-title":"Pharmacol. Rev."},{"key":"8085_CR27","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1037\/pha0000234","volume":"27","author":"LR Gerak","year":"2019","unstructured":"Gerak, L. R., Collins, G. T., Maguire, D. R. & France, C. P. Effects of lorcaserin on reinstatement of responding previously maintained by cocaine or remifentanil in rhesus monkeys. Exp. Clin. Psychopharmacol. 27, 78\u201386 (2019).","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"8085_CR28","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1151\/spp021113","volume":"1","author":"TR Kosten","year":"2002","unstructured":"Kosten, T. R. & George, T. P. The neurobiology of opioid dependence: Implications for treatment. Sci. Pract. Perspect. 1, 13\u201320 (2002).","journal-title":"Sci. Pract. Perspect."},{"key":"8085_CR29","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2174\/1874473708666150107121331","volume":"7","author":"A Garcia-Romeu","year":"2015","unstructured":"Garcia-Romeu, A., Griffiths, R. & Johnson, M. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. CDAR 7, 157\u2013164 (2015).","journal-title":"CDAR"},{"key":"8085_CR30","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2174\/1874473711666180612075954","volume":"11","author":"L Beraldo","year":"2019","unstructured":"Beraldo, L. et al. Spirituality, religiosity and addiction recovery: Current perspectives. Curr. Drug Res. Rev. 11, 26\u201332 (2019).","journal-title":"Curr. Drug Res. Rev."},{"key":"8085_CR31","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1080\/10550490600754325","volume":"15","author":"M Galanter","year":"2006","unstructured":"Galanter, M. Spirituality and addiction: A research and clinical perspective. Am. J. Addict. 15, 286\u2013292 (2006).","journal-title":"Am. J. Addict."},{"key":"8085_CR32","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1007\/s10943-019-00876-w","volume":"58","author":"BJ Grim","year":"2019","unstructured":"Grim, B. J. & Grim, M. E. Belief, behavior, and belonging: How faith is indispensable in preventing and recovering from substance abuse. J. Relig. Health 58, 1713\u20131750 (2019).","journal-title":"J. Relig. Health"},{"key":"8085_CR33","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1177\/0269881119827891","volume":"33","author":"D Erritzoe","year":"2019","unstructured":"Erritzoe, D. et al. Recreational use of psychedelics is associated with elevated personality trait openness: Exploration of associations with brain serotonin markers. J. Psychopharmacol. 33, 1068\u20131075 (2019).","journal-title":"J. Psychopharmacol."},{"key":"8085_CR34","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1080\/02791072.2020.1842569","volume":"53","author":"PG Johnstad","year":"2021","unstructured":"Johnstad, P. G. The psychedelic personality: Personality structure and associations in a sample of psychedelics users. J. Psychoact. Drugs 53, 97\u2013103 (2021).","journal-title":"J. Psychoact. Drugs"},{"key":"8085_CR35","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/02791072.2006.10399838","volume":"38","author":"M Lerner","year":"2006","unstructured":"Lerner, M. & Lyvers, M. Values and beliefs of psychedelic drug users: A cross-cultural study. J. Psychoact. Drugs 38, 143\u2013147 (2006).","journal-title":"J. Psychoact. Drugs"},{"key":"8085_CR36","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/02791072.2017.1312643","volume":"49","author":"MM Nour","year":"2017","unstructured":"Nour, M. M., Evans, L. & Carhart-Harris, R. Psychedelics, personality and political perspectives. J. Psychoact. Drugs 49, 182\u2013191 (2017).","journal-title":"J. Psychoact. Drugs"},{"key":"8085_CR37","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.addbeh.2005.08.005","volume":"31","author":"TFM ter Bogt","year":"2006","unstructured":"ter Bogt, T. F. M., Engels, R. C. M. E. & Dubas, J. S. Party people: Personality and MDMA use of house party visitors. Addict. Behav. 31, 1240\u20131244 (2006).","journal-title":"Addict. Behav."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-08085-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-08085-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-08085-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T23:47:35Z","timestamp":1669333655000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-08085-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,7]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["8085"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-08085-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,7]]},"assertion":[{"value":"31 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4099"}}